A recent Neurology digest,
as sent to subscribers

Study Type: Cross-sectional cohort study

Key Question: How does frequency-specific functional connectivity in cortical networks change across Parkinson's disease stages and relate to clinical symptoms?

Key Findings:

• Three distinct networks showed divergent trajectories: α-band prefrontal/parieto-temporal network exhibited progressive hypoconnectivity correlating with cognitive/axial impairment; β-band sensorimotor network showed progressive hyperconnectivity paralleling bradykinesia severity
• High-γ network demonstrated early hyperconnectivity followed by progressive breakdown, inversely associated with motor complications
• Multiband integration achieved near-perfect discrimination between early PD and controls, with band-specific networks predicting clinical milestones including cognitive decline and motor complications

Clinical Relevance: High-density EEG connectivity analysis could provide a scalable biomarker for PD diagnosis, staging, and risk stratification in NHS neurology services, potentially enabling earlier intervention and personalised treatment approaches.

Limitations: Cross-sectional design limits assessment of true disease progression and causality.

Study Type: Nested case-control study

Key Question: Does the gut virome composition differ between individuals with Parkinson's disease, prodromal Parkinson's disease, and healthy controls?

Key Findings:

• Four viral genome bins showed significant associations with PD: three elevated (MVG081219, MVG041501, MVG081211 with β coefficients 0.66-0.95) and one depleted (MVG098915, β = -1.42)
• Similar viral patterns were observed in prodromal PD, suggesting early gut virome changes precede clinical diagnosis
• Novel metagenomic profiling method (BAQLaVa) successfully identified viral biomarker candidates from prospectively collected samples

Clinical Relevance: This research identifies potential gut virome biomarkers that could aid early PD detection and risk stratification, particularly relevant for NHS movement disorder services developing precision medicine approaches.

Limitations: Relatively small sample sizes (62 PD cases, 90 prodromal cases) may limit generalisability and require validation in larger, more diverse populations.

Study Type: Prospective cross-sectional cohort study with validation cohorts

Key Question: Can proteomic analysis identify disease-specific biomarkers for idiopathic intracranial hypertension and provide insights into its pathophysiology?

Key Findings:

• Machine learning identified 20 IIH-predicting proteins achieving high diagnostic accuracy (AUC 0.84-0.99) in serum and CSF, distinguishing IIH patients from controls and other conditions with raised intracranial pressure
• Serum carbonic anhydrases 1 and 2 were significantly upregulated in IIH patients, suggesting CSF hypersecretion as a pathophysiological mechanism
• Neuronal injury markers (amyloid precursor protein, S100P, S100A12) were elevated, confirming IIH's non-benign nature

Clinical Relevance: This study provides the first validated biomarker panel for IIH diagnosis and supports the mechanistic rationale for acetazolamide therapy, potentially improving diagnostic accuracy and therapeutic monitoring in UK neurology practice.

Limitations: The study population was limited to Danish tertiary centres, which may affect generalisability to broader UK NHS populations.

Study Type: Genome-wide association study (GWAS) with functional validation

Key Question: What genetic variants are associated with delayed cerebral ischaemia (DCI) following aneurysmal subarachnoid haemorrhage?

Key Findings:

• One genome-wide significant variant (rs7636350) near COL6A6 and PIK3R4 genes increased DCI risk by 75% (OR 1.75, 95% CI 1.43-2.13, p=4.47×10⁻⁸) in 1,879 aSAH patients
• DCI prevalence was 22.8% across the cohort
• Hypermethylation at cg23181900 within COL6A6 was associated with DCI, suggesting epigenetic regulation

Clinical Relevance: This identifies the first genome-wide significant genetic risk factor for DCI, potentially informing risk stratification and targeted therapeutic development for post-aSAH care in UK neurocritical care units.

Limitations: European ancestry only limits generalisability to diverse UK populations.

Study Type: Experimental study with genome-wide methylation analysis and functional validation

Key Question: Does epigenetic dysregulation contribute to endothelial dysfunction and vascular fragility in brain arteriovenous malformations?

Key Findings:

• Genome-wide methylation profiling of human bAVM tissue revealed promoter-centric hypomethylation, particularly of NINJ1 (Nerve Injury-Induced Protein 1)
• NINJ1 overexpression in human brain microvascular endothelial cells enhanced proliferation, migration, tube formation, and endothelial permeability while reducing barrier proteins VE-cadherin and ZO-1
• NINJ1 mechanistically enhanced KRAS-MAPK/ERK signalling by increasing KRAS protein stability; zebrafish models confirmed that endothelial ninj1 overexpression impaired vascular integrity and induced intracranial haemorrhage

Clinical Relevance: This identifies a novel epigenetic mechanism underlying bAVM pathogenesis that could inform future therapeutic targets for preventing haemorrhage in young patients presenting to UK neurology services.

Limitations: Findings require validation in larger patient cohorts and translation to clinically applicable therapeutic interventions.

Study Type: Multi-ancestry genetic association study

Key Question: Does SORL1 genetic variation contribute to risk across multiple neurodegenerative diseases beyond Alzheimer's disease?

Key Findings:

• Analysis of 67,749 cases (15,043 AD, 9,943 related dementias, 42,763 PD) and 111,969 controls across 11 ancestries identified 53 potentially disease-related SORL1 variants (41 novel)
• Ten variants showed nominal association with AD and 5 with PD, with burden analysis revealing nominal PD association in South Asian populations (P = 0.048)
• Family-based analysis identified rare predicted-damaging variants segregating in East Asian and European PD families, though without statistically significant case-control enrichment

Clinical Relevance: Expands SORL1's therapeutic relevance beyond Alzheimer's disease to broader neurodegeneration, potentially informing precision medicine approaches for UK's diverse patient population.

Limitations: Most associations were nominally significant without correction for multiple testing, and rare variant frequencies limited statistical power for definitive conclusions.

Study Type: Longitudinal cohort study

Key Question: Can clinical progression markers derived from a Disease Course Map model predict phenoconversion and correlate with neurodegeneration biomarkers in patients with isolated REM sleep behaviour disorder?

Key Findings:

• Three individual clinical markers (time shift, acceleration factor, and intermarker spacing) achieved 73% accuracy in distinguishing between patients who phenoconverted to overt α-synucleinopathy versus those who remained stable
• Motor scores progressed 35% faster than cognitive scores; converters showed faster and earlier disease progression with motor deterioration preceding cognitive decline
• Earlier disease progression correlated with presynaptic dopaminergic impairment and increased theta band (4-8 Hz) EEG synchronisation at baseline

Clinical Relevance: These validated clinical markers could serve as efficacy endpoints in disease-modifying trials for Parkinson's disease and provide individualised progression monitoring for iRBD patients in movement disorder clinics.

Limitations: The study focused on a specific patient population (iRBD) which may limit generalisability to other prodromal α-synucleinopathy presentations.

Study Type: Randomized controlled trial

Key Question: Does electroacupuncture reduce pain severity compared to sham electroacupuncture in patients with postherpetic neuralgia?

Key Findings:

• Electroacupuncture showed superior pain reduction versus sham (NRS-11 decrease: -1.52 vs -0.99; adjusted difference -0.53, 95% CI -0.61 to -0.43, p<0.001)
• Response rate (≥30% pain reduction) was significantly higher with electroacupuncture (46.7% vs 24.3%; adjusted risk difference 22.4%, 95% CI 13.0-31.8%)
• Treatment benefits persisted at 1-month follow-up with no clinically significant adverse events

Clinical Relevance: This provides evidence for electroacupuncture as a non-pharmacological adjunct for PHN management, particularly relevant given limited therapeutic options and potential for reducing opioid dependence in NHS pain services.

Limitations: Study conducted entirely in Chinese tertiary centres, which may limit generalisability to UK healthcare settings and patient populations.